Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab maintenance with or without ipilimumab versus placebo in extensive-stage small cell lung cancer
NL-OMON47067Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Nivolumab, Nivolumab + ipilimumab and Placebo (3 arms). Primary endpoints: Overall survival and Blinded Independent Central Review-assessed progression-free survival. Started Oct 2016; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON47067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47067.